<DOC>
	<DOCNO>NCT00398554</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving combination chemotherapy may kill cancer cell . PURPOSE : This phase II trial study side effect well combination chemotherapy work treat young male patient Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Young Male Patients With Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety efficacy combination chemotherapy comprise vincristine , etoposide , cyclophosphamide , vinblastine , prednisone , doxorubicin hydrochloride ( VECOPA ) pediatric male patient previously untreated stage II-IV classic Hodgkin 's lymphoma . - Compare effect VECOPA v cyclophosphamide , vincristine , procarbazine hydrochloride , prednisone ( COPP ) patient . OUTLINE : This pilot , multicenter study . Patients stratify accord disease stage ( IA/B [ E ] , IIA [ E ] , IIB , IIIA v IIB [ E ] , IIIA/B [ E ] , IIIB , IVA/B ) . - Stratum 1 ( stage IA/B [ E ] , IIA [ E ] , IIB , IIIA ) : Patients receive oral prednisone day 1-15 , vincristine IV day 1 , 8 , 15 , doxorubicin hydrochloride IV 4 hour day 1 15 , etoposide IV 2 hour day 2-6 ( OEPA ) . Treatment repeat every 4 week 2 course . Beginning week 9 , patient receive VECOPA chemotherapy comprise oral prednisone day 1-14 21-34 , etoposide IV 2 hour day 1-3 , doxorubicin hydrochloride IV 2 hour day 21 , vinblastine IV cyclophosphamide IV 1 hour day 1 21 , vincristine IV day 8 29 . Patients undergo radiotherapy . - Stratum 2 ( stage IIB [ E ] , IIIA/B [ E ] , IIIB , IVA/B ) : Patients receive 2 course OEPA stratum 1 follow 2 course VECOPA ( 6-week course ) . Patients undergo radiotherapy . After completion study treatment , patient follow periodically least 6 year . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis classic Hodgkin 's lymphoma ( HL ) Intermediate advance disease ( stage I [ E ] IV ) No lymphocytepredominant HL Previously untreated disease PATIENT CHARACTERISTICS : Male No known hypersensitivity contraindication study drug No concurrent malignancies No severe concurrent disease ( e.g. , immune deficiency syndrome ) No know HIV positivity PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy radiotherapy More 30 day since prior concurrent investigational drug More 30 day since prior concurrent participation another clinical trial</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>stage II childhood Hodgkin lymphoma</keyword>
	<keyword>stage III childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>stage I childhood Hodgkin lymphoma</keyword>
	<keyword>childhood lymphocyte depletion Hodgkin lymphoma</keyword>
	<keyword>childhood mixed cellularity Hodgkin lymphoma</keyword>
	<keyword>childhood nodular sclerosis Hodgkin lymphoma</keyword>
</DOC>